Mark Paris
@geneman10.bsky.social
| Genetics PhD | Likes, posts, reposts are my own | Global Head, Oncology Search and Evaluation - Daiichi Sankyo BD
This paper by the Sheltzer lab is a constant reminder to me that everything should be questioned when it comes to targeted therapeutic disc and dev.
Off-target toxicity is a common mechanism-of-action of cancer drugs undergoing clinical trials. Science Translational Medicine 11, eaaw8412.
Off-target toxicity is a common mechanism-of-action of cancer drugs undergoing clinical trials. Science Translational Medicine 11, eaaw8412.
November 18, 2024 at 5:24 PM
This paper by the Sheltzer lab is a constant reminder to me that everything should be questioned when it comes to targeted therapeutic disc and dev.
Off-target toxicity is a common mechanism-of-action of cancer drugs undergoing clinical trials. Science Translational Medicine 11, eaaw8412.
Off-target toxicity is a common mechanism-of-action of cancer drugs undergoing clinical trials. Science Translational Medicine 11, eaaw8412.
Oh and this one too!
November 15, 2024 at 1:44 AM
Oh and this one too!
This all feels like an episode of "Industry"
November 12, 2024 at 1:00 AM
This all feels like an episode of "Industry"
We're nowing walking through a "demo journey"
We're also going to "swivel chair" at some point.
We're also going to "swivel chair" at some point.
November 12, 2024 at 12:17 AM
We're nowing walking through a "demo journey"
We're also going to "swivel chair" at some point.
We're also going to "swivel chair" at some point.
Also - I'm Mark Paris. Geneticist (non-clin). Been in industry for ~25 years. Led groups within biotech. Put onc drugs in the clinic. Was also comp intl consultant, led sales support and translational at CRO and now lead onc S&E at Daiichi Sankyo in BD (~5 years).
August 23, 2024 at 1:08 PM
Also - I'm Mark Paris. Geneticist (non-clin). Been in industry for ~25 years. Led groups within biotech. Put onc drugs in the clinic. Was also comp intl consultant, led sales support and translational at CRO and now lead onc S&E at Daiichi Sankyo in BD (~5 years).
Thanks Michael. Would be super grateful for a list of core, quality follows for bio topics. It's the only reason I'm still on X and if I can quickly build a similar community over here, it will make the transition so much faster. Thx!
August 23, 2024 at 1:05 PM
Thanks Michael. Would be super grateful for a list of core, quality follows for bio topics. It's the only reason I'm still on X and if I can quickly build a similar community over here, it will make the transition so much faster. Thx!